30 years of historical data (1995–2024) · Healthcare · Medical - Healthcare Plans
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Humana Inc. trades at 19.1x earnings, 12% below its 5-year average of 21.6x, sitting at the 54th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 19%. On a free-cash-flow basis, the stock trades at 9.6x P/FCF, 62% below the 5-year average of 25.5x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $22.9B | $30.7B | $57.0B | $65.1B | $60.0B | $54.6B | $49.4B | $39.6B | $36.1B | $30.8B | $27.0B |
| Enterprise Value | $31.8B | $39.6B | $62.5B | $69.1B | $67.2B | $56.0B | $50.3B | $41.7B | $36.8B | $30.7B | $28.2B |
| P/E Ratio → | 19.09 | 25.42 | 22.89 | 23.20 | 20.46 | 16.21 | 18.23 | 23.56 | 14.76 | 50.13 | 21.15 |
| P/S Ratio | 0.19 | 0.26 | 0.54 | 0.70 | 0.72 | 0.71 | 0.76 | 0.70 | 0.67 | 0.57 | 0.50 |
| P/B Ratio | 1.40 | 1.86 | 3.49 | 4.24 | 3.73 | 3.98 | 4.10 | 3.90 | 3.67 | 2.88 | 2.61 |
| P/FCF | 9.58 | 12.83 | 19.14 | 18.87 | 65.24 | 11.67 | 10.86 | 25.40 | 10.25 | 21.85 | 78.20 |
| P/OCF | 7.73 | 10.34 | 14.31 | 14.19 | 26.53 | 9.68 | 9.35 | 18.25 | 8.92 | 15.90 | 31.08 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Humana Inc.'s enterprise value stands at 11.8x EBITDA, 18% below its 5-year average of 14.4x. The Healthcare sector median is 13.8x, placing the stock at a 14% discount on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.34 | 0.59 | 0.74 | 0.81 | 0.73 | 0.78 | 0.73 | 0.69 | 0.56 | 0.52 |
| EV / EBITDA | 11.84 | 14.72 | 14.53 | 15.65 | 16.52 | 10.73 | 12.48 | 16.05 | 8.18 | 15.22 | 9.80 |
| EV / EBIT | 18.50 | 16.63 | 16.12 | 17.40 | 18.25 | 11.46 | 13.60 | 18.27 | 8.64 | 17.64 | 10.78 |
| EV / FCF | — | 16.56 | 20.99 | 20.02 | 73.01 | 11.97 | 11.06 | 26.70 | 10.45 | 21.79 | 81.75 |
Margins and return-on-capital ratios measuring operating efficiency
Humana Inc. earns an operating margin of 1.5%. Operating margins have compressed from 3.8% to 1.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 7.4% is modest. ROIC of 5.5% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | 1.5% | 1.5% | 3.2% | 3.8% | 4.0% | 6.0% | 5.3% | 3.6% | 7.5% | 2.9% | 4.5% |
| Net Profit Margin | 1.0% | 1.0% | 2.3% | 3.0% | 3.5% | 4.4% | 4.2% | 3.0% | 4.6% | 1.1% | 2.4% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.4% | 7.4% | 15.7% | 17.8% | 19.7% | 26.1% | 24.4% | 16.8% | 23.9% | 5.8% | 12.8% |
| ROA | 2.6% | 2.6% | 5.5% | 6.4% | 7.4% | 10.5% | 9.9% | 6.4% | 9.3% | 2.5% | 5.3% |
| ROIC | 5.5% | 5.5% | 12.3% | 12.6% | 13.1% | 24.6% | 20.6% | 13.6% | 28.5% | 10.5% | 15.8% |
| ROCE | 3.7% | 3.7% | 7.5% | 8.2% | 8.5% | 14.4% | 12.7% | 12.5% | 22.7% | 9.0% | 10.1% |
Solvency and debt-coverage ratios — lower is generally safer
Humana Inc. carries a Debt/EBITDA ratio of 4.1x, which is highly leveraged (33% above the sector average of 3.1x). Net debt stands at $8.9B ($11.1B total debt minus $2.2B cash). Interest coverage of just 2.6x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.68 | 0.68 | 0.63 | 0.59 | 0.65 | 0.44 | 0.41 | 0.43 | 0.48 | 0.35 | 0.37 |
| Debt / EBITDA | 4.14 | 4.14 | 2.38 | 2.05 | 2.59 | 1.16 | 1.23 | 1.68 | 1.06 | 1.88 | 1.32 |
| Net Debt / Equity | — | 0.54 | 0.34 | 0.26 | 0.44 | 0.10 | 0.08 | 0.20 | 0.07 | -0.01 | 0.12 |
| Net Debt / EBITDA | 3.32 | 3.32 | 1.28 | 0.90 | 1.76 | 0.27 | 0.23 | 0.78 | 0.16 | -0.04 | 0.42 |
| Debt / FCF | — | 3.73 | 1.85 | 1.15 | 7.77 | 0.30 | 0.20 | 1.30 | 0.21 | -0.06 | 3.54 |
| Interest Coverage | 2.61 | 2.61 | 6.86 | 8.90 | 10.29 | 16.25 | 14.28 | 9.46 | 16.61 | 8.21 | 13.07 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | — | — | — | — | — | 0.23 | 0.43 | 0.50 | — |
| Quick Ratio | — | — | — | — | — | — | — | 0.23 | 0.43 | 0.50 | — |
| Cash Ratio | 0.23 | — | — | — | — | — | — | 0.23 | 0.43 | 0.50 | — |
| Asset Turnover | — | 2.53 | 2.26 | 2.16 | 1.87 | 2.21 | 2.23 | 2.24 | 1.98 | 2.14 | 2.20 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Humana Inc. returns 5.4% to shareholders annually — split between a 1.9% dividend yield and 3.6% buyback yield. The payout ratio of 35.7% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 5.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.9% | 1.4% | 0.8% | 0.6% | 0.6% | 0.6% | 0.6% | 0.7% | 0.6% | 0.6% | 0.6% |
| Payout Ratio | 35.7% | 35.7% | 17.3% | 14.0% | 12.1% | 9.6% | 10.7% | 15.7% | 9.0% | 28.8% | 13.5% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.2% | 3.9% | 4.4% | 4.3% | 4.9% | 6.2% | 5.5% | 4.2% | 6.8% | 2.0% | 4.7% |
| FCF Yield | 10.4% | 7.8% | 5.2% | 5.3% | 1.5% | 8.6% | 9.2% | 3.9% | 9.8% | 4.6% | 1.3% |
| Buyback Yield | 3.6% | 2.7% | 2.8% | 3.2% | 0.1% | 3.3% | 2.2% | 2.7% | 9.3% | 0.3% | 1.4% |
| Total Shareholder Yield | 5.4% | 4.1% | 3.5% | 3.8% | 0.7% | 3.9% | 2.8% | 3.4% | 9.9% | 0.9% | 2.1% |
| Shares Outstanding | — | $121M | $124M | $127M | $129M | $133M | $135M | $138M | $146M | $151M | $151M |
Compare HUM with 1 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| HUMYou | $23B | 19.1 | 11.8 | 9.6 | 100.0% | 1.5% | 7.4% | 5.5% | 4.1 |
| ELV | $71B | 12.7 | 10.9 | 22.3 | 56.2% | 3.5% | 13.3% | 8.0% | 3.8 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how HUM stacks up against sector leader Elevance Health Inc..
Start ComparisonHumana Inc.'s current P/E ratio is 19.1x. The historical average is 19.1x. This places it at the 54th percentile of its historical range.
Humana Inc.'s current EV/EBITDA is 11.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.1x.
Humana Inc.'s return on equity (ROE) is 7.4%. The historical average is 13.3%.
Based on historical data, Humana Inc. is trading at a P/E of 19.1x. This is at the 54th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Humana Inc.'s current dividend yield is 1.87% with a payout ratio of 35.7%.
Humana Inc. has 100.0% gross margin and 1.5% operating margin.
Humana Inc.'s Debt/EBITDA ratio is 4.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.